Publication - Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa Fever

VHFC researchers have published a study that demonstrates how a combination of human monoclonal antibodies that cross-react with the glycoproteins of all four clades of Lassa virus is able to rescue 100% of cynomolgus macaques when treatment is initiated at advanced stages of disease.

The study, published in Nature Medicine on September 4, 2017, was led by Dr. Thomas Geisbert at University of Texas Medical Branch and Dr. Robert Garry at Tulane University. The collaboration also included partners from the Ministry of Health and Sanitation in Sierra Leone.

Read the article in Nature Medicine.

PSD to Drupal theme